[Abstract] The latent HIV-1 viral reservoir in resting CD4 + (rCD4 + ) T cells represents a major barrier to an HIV-1 cure. There is an ongoing effort to identify therapeutic approaches that will eliminate or reduce the size of this reservoir. However, clinical investigators lack an assay to determine whether or not a decrease in the latent reservoir has been achieved. Therefore, it is critical to develop assays that can reproducibly quantify the reservoir size and changes therein, in participant's blood during a therapeutic trial. Quantification of the latent HIV viral reservoir requires a highly sensitive, cost-effective assay capable of measuring the low frequency of rCD4 + T cells carrying functional provirus. Preferably, such an assay should be such that it can be adopted for high throughput and could be adopted under conditions for use in large-scale clinical trials. While PCR-based assays are commonly used to quantify pro-viral DNA or intracellular RNA transcript, they cannot distinguish between replication-competent and defective proviruses. We have recently published a study where a reporter cell-based assay (termed TZA or TZM-bl based quantitative assay) was used to quantify inducible replication-competent latent HIV-1 in blood. This assay is more sensitive, cost-efficient, and faster than available technology, including the quantitative viral outgrowth assay or the Q-VOA. Using this assay, we show that the size of the inducible latent HIV-1 reservoir in virally suppressed participants on ART is approximately 70-fold larger than previous estimates. We describe here in detail an optimized method to quantitate latently infected cells using the TZA.
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Bio-protocol 9(10): e3232. DOI:10.21769/BioProtoc.3232 (Laird et al., 2013) cell line for viral expansion instead of activated CD4 + T cells followed by RNA measurement but this is still more time consuming and labor intensive.
We recently reported the development of a sensitive TZM-bl cell-based assay (termed TZA) (Sanyal et al., 2017) to quantify the latent HIV-1 reservoir in blood. The present protocol consists of these main parts (i) isolation of resting T cells from the blood from HIV-1 positive and negative (control) donors (Steps A1-A4); (ii) activation of these resting CD4 + T cells using a strong LRA like Anti-CD3/CD28 (Siliciano and Siliciano, 2004) antibodies and (iii) washing, counting and plating these activated cells on a TZM-bl reporter cells to quantitate replication-competent HIV-1 by measuring β-gal expression to quantify virus induced. This assay utilizes the TZM-bl cell line, which stably expresses CD4, CCR5, and CXCR4, and carries an integrated copy of the β-galactosidase (β-gal) gene under the control of an HIV-1 long terminal repeat (HIV-1 LTR) promoter that allows for the detection of inducible replication-competent HIV-1. By using TZM-bl cells, quantification of replication-competent HIV-1 can be achieved with high sensitivity (Ananworanich and Mellors, 2015) . TZA has been used to calculate fraction of inducible latent virus (fPVE) (Cillo et al., 2014; Sanyal et al., 2017) . The level of fPVE can be used to screen various LRAs in-vitro as well as help monitor their in-vivo efficacy especially during clinical trials. This assay reveals that the viral reservoir is likely much larger than previously predicted and estimated which can impact the ongoing therapeutic approaches to eradicate HIV-1.
This assay can be adapted and automated to a 384-well format further down the line to enable an efficient screening platform, which will be capable of handling multiple samples simultaneously. This will make it a high-throughput assay system. In addition, because of the low cell requirement in this system, the TZA may also be useful for quantification of replication-competent HIV-1 in the pediatric population as well as estimation of the reservoir in tissues. We are presently developing a protocol for determining the reservoir size in tissues using this assay. A. Isolation of rCD4 + T cells from patients and controls 1. Collect blood from participants in EDTA tubes. This is usually done in the hospital by nurses and then sent over for processing.
Materials and Reagents
2. Dilute the blood in DPBS (1:2). The total volume in a 40 ml tube should be 10 ml blood, 20 ml DPBS.
3. Then use 10 ml of lymphocyte separation medium or ficoll to separate the layers of cells in the blood. This is done by putting the pipette with ficoll at the bottom of the 50 ml tubes and slowly pushing the liquid in and a layer of clear ficoll will be at the bottom of the tube. The total volume of liquid will not become 50 ml in the tube.
4. Every reagent should be at room temperature before use.
5. Spin this in a centrifuge at 2,000 rpm (448 x g) for 20 min to get distinct PBMC layer which will appear in between the ficoll layer and the DPBS and serum mixture. RBC will appear at the bottom of the tube.
6. Collect the PBMCs layer and wash it again with DPBS spinning in a centrifuge at 1,000 rpm (112 x g) for 10 min. www.bio-protocol.org/e3232
Bio-protocol 9(10): e3232. DOI:10.21769/BioProtoc.3232 two 5 min separation for less than 100 million cells, rather do one-time separation through the magnet. The details of the separation are listed in the protocol that is sent with the separation kit.
9. Count the cells one more time before proceeding to the next step. B. Assess the purity of resting T cells using Flow cytometry staining. (Figure 1 2. On Day 6 from the start of culture, pull the activated T cells from the 24-well plates in 15 ml conical tubes and centrifuge at 1,000 rpm (112 x g) for 10 min to pellet the cells. www.bio-protocol.org/e3232
Notes
Bio-protocol 9(10): e3232. (Figure 3 ).
4.
After making the dilution series in 15 ml tubes, the media from the TZM-bl cell plates will have to be removed by aspiration before the patient cells are plated on it. Do not do it before you start to plate as it dries out the cells in the plate. The seventh row is usually not used and the eighth row is fresh media on the TZM-bl cells. (Figure 3 ).
5. All the dilutions will have to be in 10% RPMI. 7. Take the plates out and aspirate the media out without disturbing the cells.
8. Put back DPBS in the wells with multi-channel pipettes and lightly wash and take the washout and discard. Do this two times. Do not be very rigorous while washing as this could take the cells off from the plates.
9. Put 100 μl of Promega Beta-Glo reagent on each well and incubate in the dark for 45 min-1 h.
Try to do all these steps in very little light. This reagent is extremely sensitive to light. 
